seed
Stage
2020
Founded
1
Investors
About
Breye Therapeutics develops orally administered ophthalmology drugs, including danegaptide, aimed at protecting retinal cells and preventing vascular leakage in retinal diseases such as diabetic retinopathy and age-related macular degeneration.
Explore Breye Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.